

May 29, 2013

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (AB-56) RALPANCIZUMAB

PRONUNCIATION ral" pan siz' ue mab

THERAPEUTIC CLAIM Treatment of dyslipidemia

CHEMICAL NAMES

1. Immunoglobulin G2, anti-(human neural apoptosis-regulated proteinase 1)(human-Mus musculus monoclonal PF-05335810 heavy chain), disulfide with human-Mus musculus monoclonal PF-05335810 light chain, dimer
2. Immunoglobulin G2-kappa, anti-[human proprotein convertase subtilisin/hexin type 9 (neural apoptosis-regulated convertase 1, PC9)], humanized mouse monoclonal antibody; gamma 2 heavy chain (1-444) [humanized VH (*Homo sapiens* IGHV1-46*03 (91.8%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118)-*Homo sapiens* IGHG2*01 CH2A¹⁰⁰>S(327),CH2P¹⁰¹>S(328) (119-444)] (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.1%)-IGKJ1*01 120G>Q(100) [6.3.9] (1'-107')-IGKC*01 (108'-214')]; dimer (220-220":221-221":224-224":227-227")-tetrakisdisulfide

STRUCTURAL FORMULA

Heavy chain

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	SYMHVWRQA	PGQGLEWMGE	50
IHPSSGRTNY	NEKFKSRVTM	TRDTSTSTVY	MELSSLRSED	TAVYYCARER	100
PLYASDLWGQ	GTTVTVSSAS	TKGPSVFPLA	PCSRSTSEST	AALGCLVKDY	150
FPEPVTVSWN	SGALTSVHT	FPAVLQSSGL	YSLSSVVTVP	SSNFGTQTYT	200
CNVDHKPSNT	KVDKTVKERK	CVECPPCPAP	PVAGPSVFLF	PPKPKDTLMI	250
SRTPEVTCVV	VDSHEDPEV	QFNWYVDGVE	VHNAKTKPRE	EQFNSTFRVV	300
SVLTVVHQDW	LNGKEYCKV	SNKGLPSSIE	KTISKTKGQP	REPQVYTLPP	350
SREEMTKNQV	SLTCLVKGFY	PSDIAVEWES	NGQPENNYKT	TPPMLDSDGS	400
FFLYSKLTVD	KSRWQQGNVF	SCSVMEALH	NHYTQKSLSL	SPGK	444

Light chain


DIQMTQSPSS	LSASVGDRV	ITCKASQDVH	TAVAWYQQKP	GKAPKLLIYH	50'
ASYRYTGVPS	RFSGSGSGTD	FTFTISSLQP	EDIATYYCQQ	RYSLWRTFGQ	100'
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNIFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSK	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges

22-96	22"-96"	23'-88'	23"-88"	132-214'	132"-214"
134'-194'	134"-194"	145-201	145"-201"	220-220"	221-221"
224-224"	227-227"	258-318	258"-318"	364-422	364"-422"

Modified residues

E
1, 1"
pyroglutamic acid (Glp)



Glycosylation sites (N)

Asn-294 Asn-294"

MOLECULAR FORMULA	$C_{6422}H_{9922}N_{1730}O_{2012}S_{54}$
MOLECULAR WEIGHT	145.3 kDa
TRADEMARK	None as yet
SPONSOR	Pfizer
CODE DESIGNATIONS	RN317, PF-05335810
<u>CAS</u> REGISTRY NUMBER	1407495-04-8
WHO NUMBER	9841

gbk